Canagliflozin (Cana), an inhibitor of sodium glucose cotransporter 2 (SGLT2), is used clinically as an oral hypoglycemic agent in the treatment of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.